Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Neurobiology and therapeutic utility of neurotoxins targeting postsynaptic mechanisms of neuromuscular transmission.

Ayvazyan NM, O'Leary VB, Dolly JO, Ovsepian SV.

Drug Discov Today. 2019 Oct;24(10):1968-1984. doi: 10.1016/j.drudis.2019.06.012. Epub 2019 Jun 24. Review.

PMID:
31247153
2.

Neurobiology and therapeutic applications of neurotoxins targeting transmitter release.

Ovsepian SV, O'Leary VB, Ayvazyan NM, Al-Sabi A, Ntziachristos V, Dolly JO.

Pharmacol Ther. 2019 Jan;193:135-155. doi: 10.1016/j.pharmthera.2018.08.016. Epub 2018 Aug 25. Review.

PMID:
30149105
3.

Amyloid Plaques of Alzheimer's Disease as Hotspots of Glutamatergic Activity.

Ovsepian SV, O'Leary VB, Zaborszky L, Ntziachristos V, Dolly JO.

Neuroscientist. 2019 Aug;25(4):288-297. doi: 10.1177/1073858418791128. Epub 2018 Jul 27.

4.

A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFα-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons.

Nugent M, Yusef YR, Meng J, Wang J, Dolly JO.

Neuropharmacology. 2018 Aug;138:257-266. doi: 10.1016/j.neuropharm.2018.06.016. Epub 2018 Jun 12.

PMID:
29906413
5.

Assessing Research Collaboration through Co-authorship Network Analysis.

Fagan J, Eddens KS, Dolly J, Vanderford NL, Weiss H, Levens JS.

J Res Adm. 2018 Spring;49(1):76-99.

6.

Synaptic vesicle cycle and amyloid β: Biting the hand that feeds.

Ovsepian SV, O'Leary VB, Zaborszky L, Ntziachristos V, Dolly JO.

Alzheimers Dement. 2018 Apr;14(4):502-513. doi: 10.1016/j.jalz.2018.01.011. Epub 2018 Mar 1. Review.

PMID:
29494806
7.

Conjugate of an IgG Binding Domain with Botulinum Neurotoxin A Lacking the Acceptor Moiety Targets Its SNARE Protease into TrkA-Expressing Cells When Coupled to Anti-TrkA IgG or Fc-βNGF.

Nugent M, Wang J, Lawrence G, Zurawski T, Geoghegan JA, Dolly JO.

Bioconjug Chem. 2017 Jun 21;28(6):1684-1692. doi: 10.1021/acs.bioconjchem.7b00157. Epub 2017 May 22.

PMID:
28489355
8.

Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain.

Wang J, Meng J, Nugent M, Tang M, Dolly JO.

Sci Rep. 2017 Mar 15;7:44474. doi: 10.1038/srep44474.

9.

A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.

Al-Sabi A, Daly D, Hoefer P, Kinsella GK, Metais C, Pickering M, Herron C, Kaza SK, Nolan K, Dolly JO.

J Med Chem. 2017 Mar 23;60(6):2245-2256. doi: 10.1021/acs.jmedchem.6b01262. Epub 2017 Mar 13.

PMID:
28225274
10.

Low-Affinity Neurotrophin Receptor p75 Promotes the Transduction of Targeted Lentiviral Vectors to Cholinergic Neurons of Rat Basal Forebrain.

Antyborzec I, O'Leary VB, Dolly JO, Ovsepian SV.

Neurotherapeutics. 2016 Oct;13(4):859-870. doi: 10.1007/s13311-016-0445-3.

11.

Circumventing Brain Barriers: Nanovehicles for Retroaxonal Therapeutic Delivery.

Ovsepian SV, O'Leary VB, Ntziachristos V, Dolly JO.

Trends Mol Med. 2016 Nov;22(11):983-993. doi: 10.1016/j.molmed.2016.09.004. Epub 2016 Oct 5. Review.

PMID:
27720365
12.
13.

Porphyrin derivatives as potent and selective blockers of neuronal Kv1 channels.

Daly D, Al-Sabi A, Kinsella GK, Nolan K, Dolly JO.

Chem Commun (Camb). 2015 Jan 21;51(6):1066-9. doi: 10.1039/c4cc05639f.

PMID:
25435252
14.

New inhibitors of the Kvβ2 subunit from mammalian Kv1 potassium channels.

Alka K, Dolly JO, Ryan BJ, Henehan GT.

Int J Biochem Cell Biol. 2014 Oct;55:35-9. doi: 10.1016/j.biocel.2014.07.013. Epub 2014 Jul 24.

PMID:
25066316
15.

Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.

Dolly JO, Lawrence GW.

Neurourol Urodyn. 2014 Jul;33 Suppl 3:S14-20. doi: 10.1002/nau.22634.

PMID:
25042137
16.

Fusion of Golgi-derived vesicles mediated by SNAP-25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins in vitro.

Lawrence GW, Wang J, Brin MF, Aoki KR, Wheeler L, Dolly JO.

FEBS J. 2014 Jul;281(14):3243-60. doi: 10.1111/febs.12858. Epub 2014 Jun 13.

17.

Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator.

Ma H, Meng J, Wang J, Hearty S, Dolly JO, O'Kennedy R.

Biochem J. 2014 Sep 1;462(2):247-56. doi: 10.1042/BJ20131387.

PMID:
24844294
18.

Selective cleavage of SNAREs in sensory neurons unveils protein complexes mediating peptide exocytosis triggered by different stimuli.

Meng J, Dolly JO, Wang J.

Mol Neurobiol. 2014 Oct;50(2):574-88. doi: 10.1007/s12035-014-8665-1. Epub 2014 Mar 8.

PMID:
24604356
19.

Disruption of myelin leads to ectopic expression of K(V)1.1 channels with abnormal conductivity of optic nerve axons in a cuprizone-induced model of demyelination.

Bagchi B, Al-Sabi A, Kaza S, Scholz D, O'Leary VB, Dolly JO, Ovsepian SV.

PLoS One. 2014 Feb 3;9(2):e87736. doi: 10.1371/journal.pone.0087736. eCollection 2014.

20.

SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNFα from a human synovial sarcoma cell line.

Boddul SV, Meng J, Dolly JO, Wang J.

FEBS J. 2014 Feb;281(3):750-65. doi: 10.1111/febs.12620. Epub 2013 Dec 13.

21.

Improved lentiviral transduction of ALS motoneurons in vivo via dual targeting.

O'Leary VB, Ovsepian SV, Bodeker M, Dolly JO.

Mol Pharm. 2013 Nov 4;10(11):4195-206. doi: 10.1021/mp400247t. Epub 2013 Oct 11.

PMID:
24066863
22.

Pharmacological characteristics of Kv1.1- and Kv1.2-containing channels are influenced by the stoichiometry and positioning of their α subunits.

Al-Sabi A, Kaza SK, Dolly JO, Wang J.

Biochem J. 2013 Aug 15;454(1):101-8. doi: 10.1042/BJ20130297.

PMID:
23725331
23.

Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons.

Meng J, Wang J, Lawrence GW, Dolly JO.

FASEB J. 2013 Aug;27(8):3167-80. doi: 10.1096/fj.13-228973. Epub 2013 May 2.

PMID:
23640057
24.

Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.

Lawrence GW, Ovsepian SV, Wang J, Aoki KR, Dolly JO.

Neuropharmacology. 2013 Jul;70:287-95. doi: 10.1016/j.neuropharm.2013.02.012. Epub 2013 Feb 26.

PMID:
23485402
25.

A defined heteromeric KV1 channel stabilizes the intrinsic pacemaking and regulates the output of deep cerebellar nuclear neurons to thalamic targets.

Ovsepian SV, Steuber V, Le Berre M, O'Hara L, O'Leary VB, Dolly JO.

J Physiol. 2013 Apr 1;591(7):1771-91. doi: 10.1113/jphysiol.2012.249706. Epub 2013 Jan 14.

26.

Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.

Wang J, Zurawski TH, Meng J, Lawrence GW, Aoki KR, Wheeler L, Dolly JO.

FASEB J. 2012 Dec;26(12):5035-48. doi: 10.1096/fj.12-210112. Epub 2012 Aug 31.

PMID:
22942075
27.

Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.

Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, Lawrence GW, Dolly JO.

FEBS J. 2012 Jul;279(14):2555-67. doi: 10.1111/j.1742-4658.2012.08638.x. Epub 2012 Jun 14.

28.

Intrinsic voltage dynamics govern the diversity of spontaneous firing profiles in basal forebrain noncholinergic neurons.

Ovsepian SV, Dolly JO, Zaborszky L.

J Neurophysiol. 2012 Jul;108(2):406-18. doi: 10.1152/jn.00642.2011. Epub 2012 Apr 11.

29.

Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.

Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, Aoki KR, Dolly JO.

Biochem J. 2012 May 15;444(1):59-67. doi: 10.1042/BJ20120100.

PMID:
22360156
30.

Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain.

Dolly JO, O'Connell MA.

Curr Opin Pharmacol. 2012 Feb;12(1):100-8. doi: 10.1016/j.coph.2011.11.001. Epub 2011 Dec 19. Review.

PMID:
22188874
31.

Dendritic SNAREs add a new twist to the old neuron theory.

Ovsepian SV, Dolly JO.

Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19113-20. doi: 10.1073/pnas.1017235108. Epub 2011 Nov 11. Review.

32.

Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission.

Lawrence GW, Ovsepian SV, Wang J, Aoki KR, Dolly JO.

Biochem J. 2012 Jan 1;441(1):443-52. doi: 10.1042/BJ20111117.

PMID:
21929507
33.

Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.

Dolly JO, Wang J, Zurawski TH, Meng J.

FEBS J. 2011 Dec;278(23):4454-66. doi: 10.1111/j.1742-4658.2011.08205.x. Epub 2011 Jul 5.

34.

Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons.

O'Leary VB, Ovsepian SV, Raghunath A, Huo Q, Lawrence GW, Smith L, Dolly JO.

Gene Ther. 2011 Jul;18(7):656-65. doi: 10.1038/gt.2011.8. Epub 2011 Mar 3.

PMID:
21368902
35.

Position-dependent attenuation by Kv1.6 of N-type inactivation of Kv1.4-containing channels.

Al-Sabi A, Kaza S, Le Berre M, O'Hara L, Bodeker M, Wang J, Dolly JO.

Biochem J. 2011 Sep 1;438(2):389-96. doi: 10.1042/BJ20102169.

PMID:
21352098
36.

A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.

Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM, Finn DP, Wheeler L, Dolly JO.

J Biol Chem. 2011 Feb 25;286(8):6375-85. doi: 10.1074/jbc.M110.181784. Epub 2010 Dec 7.

37.

Substrate profiling and aldehyde dismutase activity of the Kvβ2 subunit of the mammalian Kv1 potassium channel.

Alka K, Ryan BJ, Dolly JO, Henehan GT.

Int J Biochem Cell Biol. 2010 Dec;42(12):2012-8. doi: 10.1016/j.biocel.2010.09.002. Epub 2010 Sep 15.

PMID:
20833259
38.

Arrangement of Kv1 alpha subunits dictates sensitivity to tetraethylammonium.

Al-Sabi A, Shamotienko O, Dhochartaigh SN, Muniyappa N, Le Berre M, Shaban H, Wang J, Sack JT, Dolly JO.

J Gen Physiol. 2010 Sep;136(3):273-82. doi: 10.1085/jgp.200910398.

39.

Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.

Lawrence GW, Aoki KR, Dolly JO.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1080-6. doi: 10.1124/jpet.110.169342. Epub 2010 Jun 24.

PMID:
20576797
40.

Transglutaminase participates in the blockade of neurotransmitter release by tetanus toxin: evidence for a novel biological function.

Facchiano F, Deloye F, Doussau F, Innamorati G, Ashton AC, Dolly JO, Beninati S, Facchiano A, Luini A, Poulain B, Benfenati F.

Amino Acids. 2010 Jun;39(1):257-69. doi: 10.1007/s00726-009-0436-3. Epub 2010 Jan 19.

PMID:
20084413
41.

Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics.

Dolly JO, Lawrence GW, Meng J, Wang J, Ovsepian SV.

Curr Opin Pharmacol. 2009 Jun;9(3):326-35. doi: 10.1016/j.coph.2009.03.004. Epub 2009 Apr 23. Review.

PMID:
19394272
42.

Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential.

Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, Dolly JO.

J Neurosci. 2009 Apr 15;29(15):4981-92. doi: 10.1523/JNEUROSCI.5490-08.2009.

43.

How to validate a heteromeric ion channel drug target: assessing proper expression of concatenated subunits.

Sack JT, Shamotienko O, Dolly JO.

J Gen Physiol. 2008 May;131(5):415-20. doi: 10.1085/jgp.200709939. Epub 2008 Apr 14. No abstract available.

44.

Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.

Wang J, Meng J, Lawrence GW, Zurawski TH, Sasse A, Bodeker MO, Gilmore MA, Fernández-Salas E, Francis J, Steward LE, Aoki KR, Dolly JO.

J Biol Chem. 2008 Jun 20;283(25):16993-7002. doi: 10.1074/jbc.M710442200. Epub 2008 Apr 8.

45.

Adeno-associated virus transfer of a gene encoding SNAP-25 resistant to botulinum toxin A attenuates neuromuscular paralysis associated with botulism.

Raghunath A, Perez-Branguli F, Smith L, Dolly JO.

J Neurosci. 2008 Apr 2;28(14):3683-8. doi: 10.1523/JNEUROSCI.5690-07.2008.

46.
47.

Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.

Meng J, Wang J, Lawrence G, Dolly JO.

J Cell Sci. 2007 Aug 15;120(Pt 16):2864-74. Epub 2007 Jul 31.

48.

Concatemers of brain Kv1 channel alpha subunits that give similar K+ currents yield pharmacologically distinguishable heteromers.

Sokolov MV, Shamotienko O, Dhochartaigh SN, Sack JT, Dolly JO.

Neuropharmacology. 2007 Aug;53(2):272-82. Epub 2007 May 21.

PMID:
17637465
49.

The structure and mode of action of different botulinum toxins.

Dolly JO, Aoki KR.

Eur J Neurol. 2006 Dec;13 Suppl 4:1-9. Review.

PMID:
17112344
50.

Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E.

Lawrence G, Wang J, Chion CK, Aoki KR, Dolly JO.

J Pharmacol Exp Ther. 2007 Jan;320(1):410-8. Epub 2006 Oct 18.

PMID:
17050783

Supplemental Content

Support Center